This webinar describes the optimization and validation of two commercially available clinical research next-generation sequencing (NGS) assays. The first assay is aimed at identifying fusion transcripts and can identify novel fusion partners. The second assay is used to detect pharmacogenomic targets in cancers that have not responded to current standard treatment. This webinar focuses on sarcoma samples, but the approaches used are applicable to different cancer types including other solid tumors and hematological malignancies.

View related videos

• Propelling progress with RNA Sequencing

View related information

• TruSight RNA Fusion Panel
• Cancer Cytogenetics Solutions
• Introduction to Cytogenomics

Subscribe to the Illumina video channel

For more information on NGS and Sarcoma Research:

• Sarcoma Foundation of America
• Sarcoma Alliance
• Angiosarcoma Project
• Biology of Osteosarcoma Registry and Biobank
• Stories from a Sarcoma Medical Oncologist